SESSION TITLE: Airways 3
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: The efficacy and safety of once-daily tiotropium + olodaterol (T+O) in moderate to very severe COPD were demonstrated in the pivotal, Phase III TONADO studies. Preventing exacerbations is a key aim of COPD management due to their adverse effects on lung function and patients’ health status. We investigated characteristics of patients with/without COPD exacerbations in the TONADO studies.